Bone events halt OncoMed early 'Wnt' studies; shares drop

Shares of OncoMed Pharmaceuticals plummeted 25% on 13 June after the cancer drug developer revealed it had voluntarily stopped patient enrollment and dosing in its ongoing Phase I trials testing two Wnt pathway inhibitors – vantictumab (anti-Fzd7, OMP-18R5) and Fzd8-Fc (OMP-54F28) – following reports of mild-to-moderate adverse bone-related events.